Adverse health outcomes across the life course in individuals with six rare bone diseases: a 10-year population-based cohort study
Authors' conclusion
The studied rare bone diseases are associated with distinct, disease-specific hospitalization patterns and substantially worse in-hospital outcomes across the lifespan.
Study context
- Population
- Children and adults hospitalized with six rare bone diseases, national hospitalization data 01/2012–12/2021 (11,092,151 hospitalizations screened)admissions
- Participants
- 2,875 vs 14,375
- Exposure
- Rare bone diseases vs matched general population hospitalizations
- Rare bone diseasesn = 2,875
- Matched controlsn = 14,375reference
- Outcome
- In-hospital outcomes vs matched controls
Methodological detailsmatched on age, sex and patient complexity, national hospitalization data
- Matched on age, sex and patient complexity
- National hospitalization data
Main finding
As reported in the abstract
Rare bone diseases vs Matched controlsRelative risk (95% CI)
All-cause in-hospital mortality
2.26(1.77–2.89)
ICU admission
3.08(2.78–3.40)
Readmission
1.31(1.15–1.49)
- Hospital LOS; IQR 3-13 days
- median difference 6 days
Observational data: associations, not effects.
Further findings
Disease- and age-specific hospitalization patterns
- Malignancies diagnosed in patients with XLH
- 22.7%
- XLH: increased risk of emergency admissions in late adulthood
- Achondroplasia and fibrous dysplasia: planned admissions more frequent in early adulthood
- Fractures were the leading cause of hospitalization in osteogenesis imperfecta
Original publication
Adverse health outcomes across the life course in individuals with six rare bone diseases: a 10-year population-based cohort study. Eur J Endocrinol. Published 3 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →